Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OE-FOXO3 lentivirus
- Development stage
- Preclinical
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
OE-FOXO3 lentivirus is a gene therapy construct designed to overexpress the Forkhead box O3 (FOXO3) transcription factor within target cells. Utilizing a lentiviral vector for stable genomic integration, this tool is primarily employed in preclinical research to study the regulatory role of FOXO3 in cellular processes such as apoptosis, cell cycle progression, and stress response. In the context of oncology, particularly acute myeloid leukemia (AML), OE-FOXO3 lentivirus is used to investigate the mechanisms of chemotherapy resistance, such as that mediated by METTL3-induced m6A methylation. By artificially increasing FOXO3 expression, researchers can evaluate its potential as a therapeutic target to sensitize malignant cells to anthracyclines and other cytotoxic agents.
- Other names
- FOXO3-overexpressing lentivirusFOXO-3-overexpressing lentivirusFOXO 3-overexpressing lentivirusLV-FOXO3LV-FOXO-3LV-FOXO 3Lentiviral-FOXO3Lentiviral-FOXO-3Lentiviral-FOXO 3FOXO3 lentiviral vectorFOXO-3 lentiviral vectorFOXO 3 lentiviral vector
02
Targets
FOXO3 (Forkhead box protein O3)
Beyond the preview
Go deeper on OE-FOXO3 lentivirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OE-FOXO3 lentivirus.